dendreon corp (DNDNQ:OTC US)
Mark W. Frohlich M.D.
Former Chief Medical Officer and Executive Vice President of Research & Development, Dendreon Corp.
|Age||Total Calculated Compensation||This person is connected to 0 board members in 0 different organizations across 2 different industries.|
As of Fiscal Year 2013
Dr. Mark W. Frohlich, M.D. has been an Executive Vice President of Research & Development at Juno Therapeutics Inc. since February 2014. Dr. Frohlich has more than two decades of experience in the field of immuno-oncology. Dr. Frohlich served as the Chief Medical Officer of Dendreon Corp. since January 2008 until February 1, 2014 and as its Executive Vice President of Research and Development from March 2011 to February 1, 2014, where he led teams responsible for the ...
1301 2nd AvenuePhone: 206-256-4545
Seattle, Washington 98101
Board Members Memberships*There is no Board Members Memberships data available.
University of California-San Francisco
Harvard Medical School
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
Total Compensation*There is no Total Compensation data available.
|There is no Competitor Compensation data available.|